Karen Schreiber receives DKK 10 million

Karen
Schreiber has received  DKK 10 million for her research in order to improve Reproductive Health
Care in patients with rheumatic diseases.

It is with the greatest pleasure and
deepest respect that we pay tribute to our doctor Karen Schreiber. She has
received DKK 10 million from the Novo Nordisk Foundation. The amount will be
used to support the international study HYPATIA, which
spans several European countries.

The
study HYPATIA is a
randomized controlled study of hydroxychloroquine (Plaquenil) in pregnant patients
with antiphospholipid antibodies. These patients often suffer recurrent miscarriages,
intrauterine growth restriction, fetal death and pre-eclampsia. The HYPATIA study will
answer the question whether the addition of hydroxychloroquine to the current standard
of care can
improve pregnancy outcomes for these women.